Back to search results

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Differentiated Thyroid Cancer · Pediatric Cancer · Cancer · Cancer, Thyroid

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Arun Rangaswami, MD) · arun.rangaswami@ucsf.edu

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Meghan Donnelly) · 22DT025@chop.edu · 267-426-9343
    Contact: Principal Investigator (Theodore Laetsch, MD)

  • St. Jude Children's Research Hospital, Memphis, Tennessee, United States

    Contact: Study coordinator (Sara Helmig, MD) · Sara.Helmig@stjude.org · 901-593-3300

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Luz Castellanos, MD) · LECastellanos@mdanderson.org · 713-792-2841

  • Seattle Children's Hospital, Seattle, Washington, United States

    Contact: Study coordinator (Tyler Ketterl, MD, MS)
Study leads

  • Theodore Laetsch, MD

    Principal Investigator

    Children's Hospital of Philadelphia

View source on ClinicalTrials.gov(opens in a new tab)